MedTrace Logo

A Study of DS-3939a in Participants With Solid Tumors

NCT07739966 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-07-31

No results posted yet for this study

Summary

The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.

Conditions

  • Solid Tumor
  • Locally Advanced Non-Small Cell Lung Cancer
  • Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG

DS-3939a

DS-3939a will be administered as an IV infusion.

DRUG

Pembrolizumab

Pembrolizumab will be administered as an IV infusion.

DRUG

Carboplatin

Carboplatin will be administered as an IV infusion.

DRUG

Pemetrexed

Pemetrexed will be administered as an IV infusion.

DRUG

DS-1103a

DS-1103a will be administered as an IV infusion.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2030-07-31
Completion
2032-01-29
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07739966 on ClinicalTrials.gov